Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes

dc.contributor.authorGufford, Brandon T.
dc.contributor.authorRobarge, Jason D.
dc.contributor.authorEadon, Michael T.
dc.contributor.authorGao, Hongyu
dc.contributor.authorLin, Hai
dc.contributor.authorLiu, Yunlong
dc.contributor.authorDesta, Zeruesenay
dc.contributor.authorSkaar, Todd C.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2018-07-31T14:35:16Z
dc.date.available2018-07-31T14:35:16Z
dc.date.issued2018-03-26
dc.description.abstractRifampin is a pleiotropic inducer of multiple drug metabolizing enzymes and transporters. This work utilized a global approach to evaluate rifampin effects on conjugating enzyme gene expression with relevance to human xeno- and endo-biotic metabolism. Primary human hepatocytes from 7 subjects were treated with rifampin (10 μmol/L, 24 hours). Standard methods for RNA-seq library construction, EZBead preparation, and NextGen sequencing were used to measure UDP-glucuronosyl transferase UGT, sulfonyltransferase SULT, N acetyltransferase NAT, and glutathione-S-transferase GST mRNA expression compared to vehicle control (0.01% MeOH). Rifampin-induced (>1.25-fold) mRNA expression of 13 clinically important phase II drug metabolizing genes and repressed (>1.25-fold) the expression of 3 genes (P < .05). Rifampin-induced miRNA expression changes correlated with mRNA changes and miRNAs were identified that may modulate conjugating enzyme expression. NAT2 gene expression was most strongly repressed (1.3-fold) by rifampin while UGT1A4 and UGT1A1 genes were most strongly induced (7.9- and 4.8-fold, respectively). Physiologically based pharmacokinetic modeling (PBPK) was used to simulate the clinical consequences of rifampin induction of CYP3A4- and UGT1A4-mediated midazolam metabolism. Simulations evaluating isolated UGT1A4 induction predicted increased midazolam N-glucuronide exposure (~4-fold) with minimal reductions in parent midazolam exposure (~10%). Simulations accounting for simultaneous induction of both CYP3A4 and UGT1A4 predicted a ~10-fold decrease in parent midazolam exposure with only a ~2-fold decrease in midazolam N-glucuronide metabolite exposure. These data reveal differential effects of rifampin on the human conjugating enzyme transcriptome and potential associations with miRNAs that form the basis for future mechanistic studies to elucidate the interplay of conjugating enzyme regulatory elements.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationGufford, B. T., Robarge, J. D., Eadon, M. T., Gao, H., Lin, H., Liu, Y., … Skaar, T. C. (2018). Rifampin modulation of xeno‐ and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes. Pharmacology Research & Perspectives, 6(2), e00386. http://doi.org/10.1002/prp2.386en_US
dc.identifier.urihttps://hdl.handle.net/1805/16888
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/prp2.386en_US
dc.relation.journalPharmacology Research & Perspectivesen_US
dc.rightsAttribution 3.0 United States
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/us
dc.sourcePMCen_US
dc.subjectPBPK modelingen_US
dc.subjectDrug metabolizing enzyme inductionen_US
dc.subjectmiRNA modulation of mRNAen_US
dc.subjectPhase 2 enzyme inductionen_US
dc.subjectRifampin mRNA repressionen_US
dc.subjectRifampin miRNA inductionen_US
dc.titleRifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytesen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PRP2-6-e00386.pdf
Size:
3.05 MB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: